41128 - Sequencing Success in IgAN: Aligning Mechanisms with Clinical Strategy



Tuesday, October 27, 2026, 8:00 AM - Tuesday, October 26, 2027, 11:59 PM


Immunoglobulin A nephropathy (IgAN) is a progressive, immune-mediated kidney disease driven by complex mechanisms, including galactose-deficient immunoglobulin A1 production, complement formation and activation, inflammatory injury, and—as recent evidence reveals—maladaptive chronic kidney disease mechanisms such as glomerular hypertension and proteinuria-induced tubulointerstitial injury. Novel targeted therapies, including complement inhibitors, endothelin receptor antagonists, and APRIL/BAFF-directed agents, are paving the way for precision medicine in IgAN management. Meanwhile, agents in phase 3 trials target multiple steps in IgAN pathogenesis, from pathogenic IgA1 production through glomerular injury. How can healthcare providers integrate these advances into care to improve long-term outcomes for patients with IgAN?

In this PeerView educational activity, a leading expert unpacks the latest data on approved and emerging targeted therapies for IgAN and provides a practical framework for their integration into care. Through immersive, case-based learning, the expert highlights the goals of treatment, proteinuria and nephron loss management, and appropriate monitoring and follow-up. Come away with the tools to recognize the immunopathogenesis of IgAN, implement risk-stratified, mechanism-informed treatment strategies, and individualize therapeutic sequencing to optimize outcomes for your patients with IgAN.



Objectives
As a result of participating in this activity, participants should be able to:

  1. Recognize the immunopathogenesis of IgAN, including the four-hit hypothesis, dysregulated B-cell and mucosal immune responses, and the roles of APRIL, BAFF, complement activation, and endothelin signaling in driving disease progression.
  2. Evaluate the clinical evidence supporting emerging and recently approved targeted therapies for IgAN, including complement inhibitors, endothelin receptor antagonists, and APRIL/BAFF-directed agents, in the context of persistent proteinuria and residual risk despite optimized supportive care.
  3. Apply risk-stratified, mechanism-informed treatment strategies to individualize therapeutic sequencing in IgAN, integrating patient-specific factors and evolving guideline recommendations to optimize long-term renal outcomes.


AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)


Specialties - Nephrology, Primary Care
Professions - Physician


There are no fees for participating in and receiving CME credit for this online activity.



The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The University of Cincinnati and PVI, PeerView Institute for Medical Education are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.



COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months.

All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interest cannot be mitigated.

*Ineligible Companies: Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners

PVI, PeerView Institute for Medical Education

Maryn Alberts – Managing Editor
Sarah L. Anderson, PharmD – Medical Director
Alisha Roepke – Educational Program Director
Pamela DesRoche – Educational Program Manager

PeerView staff do not have any relationships to report.

University of Cincinnati Center for Continuous Professional Development/CME

Suzanne M. Wernke, MD, PhD
Physician Reviewer

Suzanne Wernke, MD, PhD, disclosed relevant financial relationships consisting of publicly traded holdings in Merck, Moderna, Pfizer, and Novo Nordisk. The relationships were reviewed, and appropriate mitigation measures were implemented.

Robert V. Ellis, MD – Physician Reviewer
Jackie Knapke, PhD – Associate Dean
Heather Muskopf – Program Director
Suzanne Matthey – Program Manager

University of Cincinnati reviewers and staff do not have any relationships to report.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.